Floatz logo

Alirocumab

Inherited Lipid Metabolism Disorder

Population Health Research Institutemonoclonal_antibodyPhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Inherited Lipid Metabolism Disorder cohort.

Asset / SponsorPhaseRating
Atorvastatin
Johns Hopkins University
Phase 4A
Rosuvastatin
Korea University Anam Hospital
Phase 4A
Metformin
RenJi Hospital
Phase 4BBB
Simvastatin
Eli Lilly and Company
Phase 4BBB
Ezetimibe
Samsung Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Alirocumab is also rated in:

acute coronary syndromeDormant
BB
Indicative · Phase 4
65 / 100
View asset →
cerebral atherosclerosisActive
B
Indicative · Phase 2
59 / 100
View asset →
cardiovascular disorderDormant
B
Indicative · Phase 3
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →